<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102982</url>
  </required_header>
  <id_info>
    <org_study_id>Shandong PH</org_study_id>
    <nct_id>NCT04102982</nct_id>
  </id_info>
  <brief_title>Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer</brief_title>
  <acronym>MWA in NSCLC</acronym>
  <official_title>Shandong Provincial Hospital Affiliated to Shandong University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on
      day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the
      primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21
      days.

      The primary end point is overall survival. The second end points include progression free
      survival, objective response rate and safety.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1：Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days.
Arm 2：Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>The proportion of Patients achieved complete response or partial response up to 16 weeks</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of first documented date of death from any cause，assessed up to 24 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>The proportion and grade of patients had adverse events up to 24 months</time_frame>
    <description>The adverse events of both microwave and camrelizumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Microwave ablation plus camrelizumab group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camrelizumab group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the group are treated with camrelizumab alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Patients will be treated with camrelizumab alone.</description>
    <arm_group_label>Camrelizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Camrelizumab plus microwave ablation</intervention_name>
    <description>In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.</description>
    <arm_group_label>Microwave ablation plus camrelizumab group</arm_group_label>
    <other_name>Camrelizumab plus MWA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 75 years old

          2. Cytologically or pathologically verified non-small cell lung cancer (NSCLC)

          3. Patients with distant metastases or postoperative recurrence

          4. EGFR or ALK sensitive mutations are negative (all patients, including
             non-adenocarcinoma patients)

          5. At least one line of platinum-based doublet chemotherapy was administrated

          6. Eastern Cancer Cooperative Group（ECOG）Performance Status（PS）of 0 to 1

          7. At least two measurable tumors (in other words a measurable tumor lesion exclusive
             primary tumors)

          8. Asymptomatic brain metastases or symptomatic brain metastases under control

          9. If treated with irradiation，at least one month interval between radiation and
             randomization 10）Cardiopulmonary function, laboratory test indicators without ablation
             or chemotherapy contraindications

        11) Informed conssent can be obtained 12) Sufficient tissue specimens for PD-L1 or TMB or
        blood samples were provided (1 week before treatment, 1 week after ablation, and once every
        two months for immune evaluation) for subsequent analysis

        Exclusion Criteria:

          1. Mixed lung cancer contains neuroendocrine tumor, small cell lung cancer or sarcoma

          2. Suffering from other malignant tumors within five years

          3. EGFR, ALK sensitive mutations are positive or unknown

          4. ECOG PS≥2

          5. Uncontrolled pleural effusion or pericardial effusion

          6. Uncontrolled symptomatic brain metastases

          7. Previously anti-PD-1, anti-PD-L1, anti-CTLA-4 or Car-T immunotherapy

          8. severe interstitial pneumonia with severe diffuse dysfunction

          9. Autoimmune diseases require long-term hormone therapy patients

         10. Patients required consistent application of prednisone

         11. Uncontrolled pulmonary infection or antibiotics stopped within 1 month

         12. Acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction
             and acute coronary syndrome within 1 month

         13. Patients during pregnancy or lactation

         14. Life expectance of 3 months or less
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Ye</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Ye</last_name>
    <phone>+8653168773171</phone>
    <email>yexitaian2014@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhigang Wei</last_name>
    <phone>+8653168773171</phone>
    <email>weizhigang321321@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Binzhou Medical University Hospital</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>+86 256600</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dezhou People's Hospital</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Dezhou</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <zip>+86 253000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Military General Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+83 250001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Shandong Academy of Medical Sciences</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86 250001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital affliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>+86053168773172</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>+86 272000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaocheng Cancer Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>+86 252000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affliated Hospital of Taishan Medical University</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Liberation Army 88 Hospital</name>
      <address>
        <city>Taian</city>
        <state>Shandong</state>
        <zip>+86 271000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>+86 262000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>+86 264000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tengzhou center of people's hospital</name>
      <address>
        <city>Zaozhuang</city>
        <state>Shandong</state>
        <zip>+86 277000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 28, 2019</last_update_submitted>
  <last_update_submitted_qc>September 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Xin Ye</investigator_full_name>
    <investigator_title>Head of Section</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>Microwave ablation</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Progression free survival</keyword>
  <keyword>Objective response rate</keyword>
  <keyword>Safety</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Principle of confidentiality</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

